For Q2 2026, TransMedics is expected to report consensus revenue of $184.17 million and earnings per share of $0.50, with the stock currently trading at $74.29 against an average analyst target of $123.25.
Investors are primarily focused on the margin performance and utilization rates of the company’s aviation-driven logistics business, which is central to its National OCS Program. This report follows a significant Q1 earnings miss where higher operational expenses and maintenance costs pressured margins despite 21% top-line growth.
Market participants are looking for evidence that the expansion of the U.S. fleet to 22 aircraft and the strategic investment in PAD Aviation will begin to restore profitability through improved logistics efficiency and international scaling.